Saving Seniors Money on Prescriptions Act
HB950, the “Saving Seniors Money on Prescriptions Act,” would add new federal reporting and audit requirements for pharmacy benefit managers (PBMs) that serve Medicare Part D prescription drug plans and Medicare Advantage prescription drug plans (MA-PD plans). Beginning with plan years on or after January 1, 2028, PBMs would have to operate under written agreements with plan sponsors that require detailed transparency about pricing guarantees, rebates, discounts, direct and indirect remuneration, affiliate pharmacy use, formulary treatment of brand-name drugs versus generics and biosimilars, and other benefit design features that may steer enrollees to affiliated pharmacies.
The bill requires annual, machine-readable reports to plan sponsors and, upon request, to the Secretary of Health and Human Services. Those reports would include extensive drug-level data such as utilization, dispensing channel, acquisition costs, wholesale prices, enrollee out-of-pocket spending, rebates, pharmacy reimbursement amounts, NADAC data, and revenue retained by PBMs and affiliates. It also requires disclosures about affiliated entities, brokers and consultants paid by PBMs, 340B-related arrangements, and written justifications when a plan gives more favorable coverage to a brand or reference product than to lower-cost generic or biosimilar alternatives. The bill also gives plan sponsors audit rights and imposes contractual and financial consequences if PBMs fail to comply.
In addition to the PBM reporting mandate, the bill directs the Comptroller General to study federal and state reporting requirements related to prescription drug cost transparency and to report back to Congress within two years with recommendations to streamline and reduce compliance burdens. The bill would amend the Social Security Act, specifically Medicare Part D provisions, and would also apply the new PBM reporting framework to MA-PD plans through cross-reference.
The general sentiment reflected by the bill’s title and structure is strongly pro-transparency and consumer-cost reduction, with an emphasis on lowering prescription drug costs for seniors. There is no recorded committee debate or vote history in the provided materials, so no formal opposition or support is documented here. The bill appears designed to appeal to concerns about PBM opacity, affiliate steering, and the gap between gross drug spending and what beneficiaries actually pay.
Likely points of contention include the breadth and complexity of the reporting obligations, the administrative burden on PBMs and plan sponsors, confidentiality limits, and the potential overlap with existing federal and state disclosure regimes. The required GAO study suggests lawmakers are aware that PBMs and health plans may already face multiple reporting frameworks and that harmonization may be needed. PBMs, affiliated pharmacies, and some plan sponsors may object to the scope of required disclosures and audit access, while patient advocates, transparency advocates, and supporters of lower drug costs are likely to favor the bill.
HB950 would amend Title XVIII of the Social Security Act to impose new Medicare Part D PBM reporting, audit, and certification requirements, and it would extend those requirements to MA-PD plans. It would create a new federal transparency framework covering drug pricing, rebates, remuneration, affiliate relationships, formulary decisions, and beneficiary cost-sharing, while also authorizing audits and contractual enforcement mechanisms. The bill would not directly set drug prices, but it would significantly expand the information PBMs and plan sponsors must collect, retain, and report, and it would likely affect PBMs, PDP sponsors, MA organizations, pharmacies, affiliates, consultants, and Medicare beneficiaries.
The bill’s overall tone is favorable toward transparency, accountability, and lowering prescription drug costs for seniors. Its short title and detailed disclosure requirements indicate a strong policy preference for exposing PBM pricing practices and affiliate relationships. No votes or committee transcripts were provided, so there is no recorded formal opposition or support in the available history; however, the structure of the bill suggests it is intended to address longstanding concerns about PBM practices and beneficiary costs.
The main areas of contention are likely to be the scope and intrusiveness of the reporting requirements, the cost of compliance, and the treatment of confidential business information. PBMs and affiliated entities may argue that the bill is overly burdensome, duplicates existing federal and state reporting, and could expose sensitive pricing and contracting information. Supporters are likely to emphasize that the bill is necessary to reveal rebate flows, affiliate steering, and differences between gross and net drug costs, especially where beneficiaries may be paying more for brand or reference products than for generics or biosimilars. The mandated GAO study also signals concern about conflicting state and federal requirements, which may be a point of debate among stakeholders.